1. |
《中国心血管健康与疾病报告2022》要点解读. 中国心血管杂志, 2023, 28(4): 297-312.
|
2. |
沈雳, 李晨光, 吴轶喆, 等. 《中国心血管医疗器械产业创新白皮书(2021)》概要. 中国介入心脏病学杂志, 2022, 30(4): 251-258.
|
3. |
中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要. 中国循环杂志, 2023, 38(6): 583-612.
|
4. |
李盼, 冯静, 许博轩, 等. 冠状动脉血管支架的研究现状. 医疗卫生装备, 2023, 44(6): 92-100.
|
5. |
周齐, 严鸿伊, 张艳丽, 等. 非劣效性设计临床试验. 中国卒中杂志, 2023, 18(6): 636-644.
|
6. |
张新佶, 贺江南, 任建玲, 等. 阳性药对照临床试验中非劣效性检验的统计分析方法及相关问题. 数理统计与管理, 2010, 29(2): 372-379.
|
7. |
Hills RK. Non-inferiority trials: No better. No worse? No change? No pain? Br J Haematol, 2017, 176(6): 883-887.
|
8. |
Mauri L, D'Agostino RB. Challenges in the design and interpretation of noninferiority trials. N Engl J Med, 2017, 377(14): 1357-1367.
|
9. |
Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009, 360(10): 961-972.
|
10. |
Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med, 2011, 364(18): 1718-1727.
|
11. |
Ellert-Gregersen J, Jensen LO, Jakobsen L, et al. Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial. EuroIntervention, 2022, 18(2): e124-e131.
|
12. |
Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA, 2012, 308(24): 2594-2604.
|
13. |
Leung JT, Barnes SL, Lo ST, et al. Non-inferiority trials in cardiology: what clinicians need to know. Heart, 2020, 106(2): 99-104.
|
14. |
Rehal S, Morris TP, Fielding K, et al. Non-inferiority trials: are they inferior. A systematic review of reporting in major medical journals. BMJ Open, 2016, 6(10): e012594.
|
15. |
Pong S, Urner M, Fowler RA, et al. Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics. BMJ Open, 2021, 11(4): e044480.
|
16. |
Althunian TA, de Boer A, Klungel OH, et al. Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials, 2017, 18(1): 107.
|
17. |
Donken R, de Melker HE, Rots NY, et al. Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials. Vaccine, 2015, 33(12): 1426-1432.
|
18. |
李新旭, 周军, 高丽丽, 等. 非劣效临床试验的总结与思考. 中国新药杂志, 2020, 29(13): 1469-1477.
|
19. |
FDA. Non-inferiority clinical trials to establish effectiveness-guidance for industry. 2016.
|
20. |
Simonato M, Ben-Yehuda O, Vincent F, et al. Consequences of inaccurate assumptions in coronary stent noninferiority trials: a systematic review and meta-analysis. JAMA Cardiol, 2022, 7(3): 320-327.
|
21. |
陈靖. 非劣效验证中基于率差和率比的界值确定方法的比较. 广州: 南方医科大学, 2012.
|
22. |
刘朋. 药物洗脱支架在经皮冠状动脉介入治疗中的应用现状. 外科研究与新技术, 2021, 10(3): 209-213.
|
23. |
Ofori S, Cafaro T, Devereaux PJ, et al. Noninferiority margins exceed superiority effect estimates for mortality in cardiovascular trials in high-impact journals. J Clin Epidemiol, 2023, 161: 20-27.
|